Emerson 2015 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2015 Emerson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 66

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66

Leaving the World
Better than We Found It
Empowering Single-Use Production in Medicine Manufacturing. Low initial
capital cost and manufacturing flexibility are critical to cost-effective biotechnology manufacturing.
Many of Emerson’s customers are pursuing “single use” unit operations with disposable “bags” to
bring development, clinical, and commercial facilities online faster and more cost effectively
than with traditional large stainless steel vessels. During manufacturing, this capability enables
switching between batches and product recipes without needing hours to clean and sterilize
equipment, providing unprecedented production flexibility. Such flexible manufacturing also requires
an automation system with industry-leading control, recipe management and software adaptability.
Several biotech companies have selected Emerson Process Management’s DeltaV™ automation
system with its comprehensive batch-processing environment and regulatory compliance capability,
making it easier – and faster – for operators to switch and prepare equipment for new batches.
The ability to run DeltaV™ in a “virtualized” mode is also allowing our customers to accelerate initial
system configuration and reduce equipment footprint, resulting in lower costs and faster project
completion timelines enabling these companies to reduce the time-to-market for life-enhancing
and life-saving products.
less footprint which
means significant
reduction in CapEx
30%
Background photograph provided by GE Healthcare12 | 2015 Annual Report